ArticleRadiation oncology (London, England)2014
CT-guidance interstitial (125)Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors.
Article in Radiation oncology (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Cancer Pain: Radiotherapy as a Double-Edged Sword.International journal of molecular sciences · 2025Review
- Utility of spectral CT with orthopedic metal artifact reduction algorithms forQuantitative imaging in medicine and surgery · 2024Article
- Monte Carlo Dosimetric Study of Percutaneous Vertebroplasty and Brachytherapy for the Treatment of Spinal Metastases.Journal of biomedical physics & engineering · 2023Article
- Comparative study of Lutetium-177 and Phosphorus-32 in radioactive bone cement for the treatment of vertebral body metastasis.Journal of cancer research and clinical oncology · 2023Article
- Re-Irradiation with Intensity-Modulated Radiation Therapy for the Treatment of Recurrent Cervical Cancer in the Pelvis: An Analysis of Outcomes and Toxicity.Medicina (Kaunas, Lithuania) · 2023Article
- Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study.Radiation oncology (London, England) · 2023Article
- Efficacy and safety of CT-guidedFrontiers in oncology · 2023Article
- Spinal brachytherapy.Neuro-oncology · 2022Article
- Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review.Current oncology (Toronto, Ont.) · 2022Review
- Multiple direction needle-path planning and inverse dose optimization for robotic low-dose rate brachytherapy.Zeitschrift fur medizinische Physik · 2022Article
- Image guidance in spine tumor surgery.Neurosurgical review · 2020Review
- Comparison of pre-implant treatment planning and post-implant dosimetry in I-125 spinal metastases brachytherapy.Oncology letters · 2020Article
- Review
- Efficacy and dosimetry analysis of image-guided radioactive ¹²⁵I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy.Journal of gynecologic oncology · 2019Article
- Side effects of CT-guided implantation ofRadiation oncology (London, England) · 2018Article
- Dosimetry Verification ofTechnology in cancer research & treatment · 2017Article
- Palliative treatment of pelvic bone tumors using radioiodine (World journal of surgical oncology · 2016Article
- Surgery Combined with Radiotherapy to Treat Spinal Tumors: A Review of Published Reports.Orthopaedic surgery · 2016Review
- The Protective Roles of ROS-Mediated Mitophagy onOxidative medicine and cellular longevity · 2016Article
- CT-GuidedBioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided (125)I seed brachytherapy for recurrent paraspinous and vertebral primary tumors.
methodsFrom November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of (125)I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of (125)I seeds were 90-183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 months (median 19 months). The local control rate was calculated by the Kaplan-Meier method.
resultsFor 5 Chondrosarcomas, the 1-, 2-, 3-year local control rates were 75%, 37.5%, and 37.5%, respectively, with a median of 34 months (range, 4-39 months). For 4 chordomas, the local control rate was 50% with a median follow-up of 13 months (range, 3-17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation, without more than Frankel grade 3 radiation myelopathy.
conclusionsPercutaneous (125)I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.